You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Should We Evaluate Cardiac Biomarkers Differently in Transgender Patients?

  • Authors: News Author: Patrice Wendling; CME Author: Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 12/2/2022
  • Valid for credit through: 12/2/2023, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for primary care physicians, nurses/nurse practitioners, pharmacists, physician assistants, cardiologists, and other clinicians who treat and manage transgender patients.

The goal of this activity is for the healthcare team members to be better able to evaluate blood levels of high-sensitivity cardiac troponin and N-terminal pro-brain natriuretic peptide among transgender adults.

Upon completion of this activity, participants will:

  • Analyze how sex can affect levels of high-sensitivity cardiac troponin and N-terminal pro-brain natriuretic peptide
  • Evaluate blood levels of high-sensitivity cardiac troponin and N-terminal pro-brain natriuretic peptide among transgender adults
  • Outline implications for the healthcare team


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

News Author

  • Patrice Wendling

    Deputy News Editor
    Medscape Medical News


    Patrice Wendling has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine


    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) ( 0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-397-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 12/2/2023. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Should We Evaluate Cardiac Biomarkers Differently in Transgender Patients?

Authors: News Author: Patrice Wendling; CME Author: Charles P. Vega, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/2/2022

Valid for credit through: 12/2/2023, 11:59 PM EST


Clinical Context

Markers of cardiac disease can be critical among patients with suspected conditions such as acute ischemia or heart failure, but patient factors also can produce variability in these laboratory values. The authors of the current study provide a review of this phenomenon, with an emphasis on sex-based differences in cardiac biomarkers.

Women generally have lower levels of high-sensitivity cardiac troponin (hs-cTn) compared with men, although the clinical significance of this difference is controversial. In contrast, levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are higher among women vs men, and this difference is maintained regardless of the presence of cardiac disease. Age is positively associated with higher NT-proBNP levels, whereas body mass index is inversely related to NT-proBNP.

What should clinicians do regarding making adjustments for hs-cTn and NT-proBNP values among transgender adults, particularly those who are using gender-affirming therapy? The current study addresses this question.

Study Synopsis and Perspective

Cardiac biomarkers vary according to sex hormones in healthy transgender adults, just as in cisgender individuals, a new cross-sectional study suggests.

Previous research in the general population has shown that females have a lower 99th percentile upper reference limit for high-sensitivity cardiac troponin (hs-cTn) than males, whereas NT-proBNP concentrations are higher in females than males across all ages after puberty.

"That trend is similar for people that have been on gender-affirming hormones, saying that sex hormones are playing a role in how cardiac turnover happens in a healthy state," study author Dina M. Greene, PhD, University of Washington, Seattle, told | Medscape Cardiology.

Although the number of transgender people seeking gender-affirming care is increasing, studies are limited and largely retrospective cohorts, she noted. The scientific literature evaluating and defining cardiac biomarker concentrations is "currently absent."

The American Heart Association's recent scientific statement on the cardiovascular (CV) health of transgender and gender diverse (TGD) people, says that mounting evidence points to worse CV health in TGD people and that part of this excess risk is driven by significant psychosocial stressors across the lifespan.[1] "In addition, the use of gender-affirming hormone therapy may be associated with cardiometabolic changes, but health research in this area remains limited and, at times, contradictory."

For the present study, Dr Greene and colleagues reached out to LGBTQ-oriented primary care and internal medicine clinics in Seattle, Washington, and Iowa City, Iowa, to recruit 79 transgender men prescribed testosterone (mean age, 28.8 years) and 93 transgender women (mean age, 35.1 years) prescribed estradiol for at least 12 months. The mean duration of hormone therapy was 4.8 and 3.5 years, respectively.

The median estradiol concentration was 51 pg/mL in transgender men and 207 pg/mL in transgender women. Median testosterone concentrations were 4.6 ng/mL and 0.4 ng/mL, respectively.

The cardiac biomarkers were measured with the ARCHITECT STAT and ACCESS high-sensitivity troponin I assays, the Elecsys Troponin T Gen 5 STAT assay, and the Elecsys ProBNP II immunoassay (Roche Diagnostics).

As reported in JAMA Cardiology, the median hs-cTnI level on the ARCHITECT STAT assay was 0.9 ng/L (range, 0.6-1.7) in transgender men and 0.6 ng/L (range, 0.3-1.0) in transgender women.[2] The pattern was consistent across the 2 other assays.

In contrast, the median NT-proBNP level was 17 ng/L (range, 13-27) in transgender men and 49 ng/L (range, 32-86) in transgender women.

"It seems that sex hormone concentration is a stronger driver of baseline cardiac troponin and NT-proBNP concentrations relative to sex assigned at birth," Dr. Greene said.

The observed differences in hs-cTn concentrations "are likely physiological and not pathological," given that concentrations between healthy cisgender people are also apparent and are not thought to portend adverse events, the authors note.

Teasing out the clinical implications of sex-specific hs-cTn upper reference limits (URLs) for ruling in acute myocardial infarction (MI), however, is complicated by biological and social factors that contribute to poorer outcomes in women, despite lower baseline levels, they add. "Ultimately, the psychosocial benefits of gender-affirming hormones are substantial, and informed consent is likely the ideal method to balance the undetermined risks."

Dr Greene pointed out that the study was not powered to accurately calculate gender-specific hs-cTn 99th percentiles or reference intervals for NT-proBNP and assessed the biomarkers at a single time.

For the transgender person presenting with chest pain, she said, the clinical implications are not yet known, but the data suggest that when sex-specific 99th percentiles for hs-cTn are used, the numeric value associated with the affirmed gender, rather than the sex assigned at birth, may be the appropriate URL.

"It really depends on what the triage pathway is and if that pathway has differences for people of different sexes and how often people get serial measurements," Dr Greene said. "Within this population, it's very important to look at those serial measurements because for people that are not cismen, those 99th percentiles when they're non-sex-specific are going to favor in detection of a heart attack. So, you need to look at the second value to make sure there hasn't been a change over time."

The observed differences in the distribution of NT-proBNP concentrations is similar to that in the cisgender population, Dr Greene noted. But these differences do not lead to sex-specific diagnostic thresholds because of the significant elevations present in overt heart failure and cardiovascular disease. "For NT-proBNP, it's not as important. People don't usually have a little bit of heart failure, they have heart failure, where people have small MIs."

Dr Greene said that she would like to see larger trials looking at biomarker measurements and cardiac imaging before hormone therapy, but that the biggest issue is the need for inclusion of transgender people in all cardiovascular trials.

"The sample sizes are never going to be as big as we get for cisgender people for a number of reasons, but ensuring that it's something that's being asked on intake and monitored over time so we can understand how transgender people fit into the general population for cardiac disease," Dr Greene said. "And so, we can normalize that they exist. I keep driving this point home, but this is the biggest thing right now when it's such a political issue."

The study was supported in part by the University of Washington, Department of Laboratory Medicine; the University of Iowa, Department of Pathology; and a grant from Abbott Diagnostics for in-kind high-sensitivity cardiac troponin I reagent. Coauthor Robert H. Christenson, PhD, reported financial relationships with Siemens Healthineers, Roche Diagnostics, Beckman Coulter, Becton, Dickinson, Abbott Diagnostics, Quidel Diagnostics, Sphingotech, and PixCell Medical. No other financial relationships were reported.

JAMA Cardiol. Published online October 5, 2022.

Study Highlights

  • Transgender patients were recruited for participation from clinic systems in Iowa and Washington with a focus on lesbian, gay, bisexual, transgender, and queer patients.
  • All participants had blood tests for hs-cTn and NT-proBNP. The goal of the study was to compare average levels of these biomarkers among transgender adults with standard levels among cisgender adults.
  • 79 transgender men in the study were receiving testosterone therapy. The mean age of this cohort was 28.8 years.
  • 93 transgender women in the study were receiving estrogen therapy. The mean age of this cohort was 35.1 years.
  • None of the participants had evidence of diabetes or chronic kidney disease. Lipid levels were similar in comparing transgender women with transgender men.
  • The median levels of hs-cTn among transgender men and transgender women were 0.9 and 0.6 ng/L, respectively. This difference was statistically significant.
  • The respective median levels of NT-proBNP levels were 17 and 49 ng/L, another statistically significant difference.
  • The authors conclude that the concentrations of hs-cTn and NT-proBNP among transgender adults are influenced by gender-affirming hormone therapy. Transgender patients receiving this therapy can be assessed using standard norms for cisgender adults in their transition gender, not by their sex defined at birth.

Clinical Implications

  • Cisgender women generally have lower levels of hs-cTn and higher levels of NT-proBNP compared with cisgender men.
  • The current study finds that hs-cTN and NT-proBNP levels among transgender women and men mirror those of cisgender adults of their transition gender.
  • Implications for the healthcare team: The healthcare team should evaluate transgender women and men using gender-affirming hormone therapy, applying cardiac biomarker norms for cisgender women and men.


Earn Credit

  • Print